Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

@article{Weidemann2014PatientsWF,
  title={Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.},
  author={F. Weidemann and J. Kr{\"a}mer and T. Duning and M. Lenders and S. Canaan-K{\"u}hl and A. Krebs and H. Guerrero Gonz{\'a}lez and C. Sommer and N. {\"U}çeyler and M. Niemann and S. St{\"o}rk and Michael Schelleckes and S. Reiermann and J. Stypmann and S. Brand and C. Wanner and E. Brand},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2014},
  volume={25 4},
  pages={
          837-49
        }
}
Because of the shortage of agalsidase-beta in 2009, many patients with Fabry disease were treated with lower doses or were switched to agalsidase-alfa. This observational study assessed end-organ damage and clinical symptoms during dose reduction or switch to agalsidase-alfa. A total of 105 adult patients with Fabry disease who had received agalsidase-beta (1.0 mg/kg body weight) for ≥1 year were nonrandomly assigned to continue this treatment regimen (regular-dose group, n=38), receive a… Expand
50 Citations
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
  • 30
  • PDF
Fabry disease under enzyme replacement therapy—new insights in efficacy of different dosages
  • J. Krämer, M. Lenders, +13 authors F. Weidemann
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2018
  • 13
  • PDF
Treatment switch in Fabry disease- a matter of dose?
Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
  • 24
  • PDF
A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease
  • 33
  • Highly Influenced
Enzyme replacement therapy for Anderson-Fabry disease.
  • 102
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.
  • 68
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
  • 53
  • PDF
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
  • 370
  • Highly Influential
  • PDF
Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
  • 58
  • Highly Influential
  • PDF
Agalsidase alfa and kidney dysfunction in Fabry disease.
  • 145
  • PDF
...
1
2
3
4
5
...